Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

Key points:<ul>
<li>Energy names are showing signs of bottoming with the recent uptick in crude, and weakness in the U.S. dollar</li>
<li>REITs are continuing to firm up as rates have plateaued</li>
<li>Biotech stocks are continuing to show leadership characteristics</li>
</ul>Charts highlighted: AFI, ODP, SPWH, CVS, KMB, THS, CHK, KMI, RRC, AXS, ESS, KIM, APTS, KRG, REGN, NERV, NSTG, RARX, AYI, CFX, AXL, PAH, FNSR, TRUE, ALK, HA, SAVE, and PEGI

Key points:
Energy names are showing signs of bottoming with the recent uptick in crude, and weakness in the U.S. dollar
REITs are continuing to firm up as rates have plateaued
Biotech stocks are continuing to show leadership characteristics
Charts highlighted: AFI, ODP, SPWH, CVS, KMB, THS, CHK, KMI, RRC, AXS, ESS, KIM, APTS, KRG, REGN, NERV, NSTG, RARX, AYI, CFX, AXL, PAH, FNSR, TRUE, ALK, HA, SAVE, and PEGI

Technically Attractive U.S. Stocks for Value Investors

Pharma/ Biotechnology Investments Specialist, Vasuda Capital Management

Dr. Bhavneesh Sharma, MD, MBA

Pharma/ Biotechnology Investments Specialist

Vasuda Capital Management

Equity Bottom-Up

We listened to <a href="https://www.smartkarma.com/entities/23716" target="_blank" data-smartkarma-citation="entities:23716:1">Cerecor Inc (CERC US)</a> management's conference call (<a href="http://ir.cerecor.com/ir-calendar/detail/756/topline-phase-2-results-for-cerc-301s-phase-2-trial-in" target="_blank">link</a>) about the phase 2 results of CERC-301 as adjunct therapy in major depressive disorder, MDD (<a href="http://ir.cerecor.com/press-releases/detail/30/cerecor-reports-top-line-data-from-cerc-301-phase-2-study" target="_blank">link to press release</a>). On closely analyzing the study data, we agree with the management's assessment that the antidepressant effect of the drug is more prominent at day 2 after oral administration and wears off slightly by day 4. We also agree that in future planned studies, the 20 mg dose of the drug may need to be given twice…

We listened to Cerecor Inc (CERC US) management's conference call (link) about the phase 2 results of CERC-301 as adjunct therapy in major depressive disorder, MDD (link to press release). On closely analyzing the study data, we agree with the management's assessment that the antidepressant effect of the drug is more prominent at day 2 after oral administration and wears off slightly by day 4. We also agree that in future planned studies, the 20 mg dose of the drug may need to be given twice…

Cerecor's Novel Drugs for Major Depression. 'Failed' Trial or Buying Opportunity in the Stock?

United States

Minerva Neurosciences, Inc. operates as a clinical-stage biopharmaceutical company. The Company develops new therapies to treat central nervous system (CNS) and neuropsychiatric diseases. Minerva Neurosciences serves communities in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Minerva Neurosciences (NERV US)

Technically Attractive U.S. Stocks for Value Investors

Key points: Energy names are showing signs of bottoming with the recent uptick in crude, and weakness in the U.S. dollar REITs are continuing to...

Vermilion Research

Cerecor's Novel Drugs for Major Depression. 'Failed' Trial or Buying Opportunity in the Stock?

We listened to Cerecor Inc (CERC US) management's conference call (link) about the phase 2 results of CERC-301 as adjunct therapy in major...

Dr. Bhavneesh Sharma, MD, MBA

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)